Cerulean Pharma Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cerulean Pharma Inc. - overview
Established
2006
Location
Waltham, MA, US
Primary Industry
Pharmaceuticals
About
Cerulean Pharma Inc. is a biopharmaceutical company focused on developing innovative cancer therapies utilizing its proprietary technology platform to deliver therapeutics efficiently and effectively. Established in 2006 and headquartered in Waltham, US, Cerulean Pharma Inc. specializes in biopharmaceuticals targeting cancer treatment.
The company underwent a strategic shift through its merger with Daré Bioscience, enhancing its clinical product offerings. The CEO, Sabrina Johnson, leads the company, which successfully raised USD 1. 50 mn in its latest funding round in April 2014, bringing the total amount raised to USD 1. 50 mn.
The company has completed 15 deals to date, with its most recent deal being a trade sale. Cerulean Pharma Inc. develops advanced cancer therapies through its proprietary drug delivery platform, focusing on improving the efficacy of therapeutic agents. Its innovative approach aims to enhance patient outcomes by delivering drugs directly to tumors while minimizing side effects, thus addressing critical needs in oncology.
In its most recent financial year, Cerulean Pharma Inc. reported a revenue of USD 9,784 mn, alongside an EBITDA of USD -23,409,160 in 2024. Cerulean Pharma plans to expand its product pipeline with new oncology therapies aimed for launch in the upcoming years. The company is also targeting expansion into additional international markets to broaden its reach and accessibility.
Recent funding from the trade sale will be utilized to support these development initiatives and enhance operational capabilities.
Current Investors
Hercules Capital, Polaris Partners, Lilly Ventures
Primary Industry
Pharmaceuticals
Sub Industries
Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.ceruleanrx.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.